Roche Shared Real-World Data for Vabysmo Study
A study of 5,000 patients confirms vision improvements across three retinal conditions.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust that new medical treatments work as well in real-world practice as in trials?
Roche has presented new real-world effectiveness data for Vabysmo at the EURETINA 2026 congress. The VOYAGER study analyzed imaging outcomes from over 5,000 patients across 28 countries.
Why it matters
The findings provide a broad look at the drug's performance outside of controlled clinical trials. The data confirm therapeutic efficacy in managing vision loss across multiple retinal diseases.
The VOYAGER study utilized AI-driven deep learning algorithms to evaluate SD-OCT (spectral-domain optical coherence tomography) imaging data. Results showed consistent improvements in vision and reductions in central subfield thickness across nAMD, DME, and RVO patient cohorts.
The players
Roche
A global healthcare firm headquartered in Basel that develops diagnostics and therapeutics, including antibody-based therapies for ophthalmology.
The details
Vabysmo functions as a bispecific antibody, a lab-engineered protein that binds to two distinct targets: Ang-2 (angiopoietin-2) and VEGF-A (vascular endothelial growth factor A). By simultaneously inhibiting these two pathways, the drug reduces vascular leakage and inflammation in the eye. Researchers used deep learning, a type of machine learning that mimics human brain patterns to process data, to automate the analysis of SD-OCT images taken during routine clinical visits.
Timeline
October 1-4, 2026: VOYAGER study findings were presented at the EURETINA 2026 congress.
The Tech Race
This development aligns with the broader industry effort to move beyond static clinical trials toward continuous real-world performance monitoring for ocular biologics. It establishes a benchmark for how pharmaceutical firms are utilizing AI-automated imaging analysis to validate drug efficacy at scale.
Patients and clinicians can view these results as supplemental evidence of Vabysmo's performance in standard care settings beyond initial clinical trials. The drug remains currently approved for use in over 100 countries for nAMD and DME, and in over 60 countries for RVO.
The takeaway
The VOYAGER findings confirm that AI-driven imaging analysis provides a scalable method for validating drug performance in global clinical populations. Watch for ongoing reviews by additional health authorities that may expand the drug's global market access.
Further reading
For more on the current landscape of ocular drug development, visit Biotech.
Live Poll
Do you trust that new medical treatments work as well in real-world practice as in trials?
